Triglycerides Mediate Body Mass Index and Nonalcoholic Fatty Liver Disease: A Population-Based Study

Overview

Journal Obes Facts

Publisher Karger

Specialty Endocrinology

Date 2021 Mar 29

PMID 33780962

Citations 11

Authors

Jie Xing

Xue Guan

Qian Zhang

Shuohua Chen

Shouling Wu

Xiujing Sun

Affiliations

Soon will be listed here.

Abstract

Introduction: Nonalcoholic fatty liver disease (NAFLD) is defined by the accumulation of triglycerides (TG). The body mass index (BMI) is associated with NAFLD. This large-scale cohort study was performed to evaluate and quantify the mediating effect of TG on the association between BMI and NAFLD.

Methods: In total, 15,943 participants in the Kailuan Group were recruited between 2010 and 2014. The impact of TG on the association between BMI and NAFLD was determined through a mediation analysis.

Results: BMI was an independent risk factor for incident NAFLD, with OR of 1.416 (95% CI 1.338-1.499) and 1.187 (95% CI 1.137-1.240) in the low-BMI and high-BMI groups, respectively (p < 0.001). The TG level was a risk factor for NAFLD in the high-BMI group, with an OR of 2.775 (95% CI 1.488-5.177; p = 0.001). Positive associations between BMI and the TG level remained in the 2 above mentioned groups after adjusting for confounders (β = 0.072 and 0.032; p < 0.001). The mediation analysis revealed that TG contributed to 26.050% of incident NAFLD in the high-BMI group (p = 0.01).

Conclusion: A high BMI was an independent risk factor for incident NAFLD, and a high TG level was a risk factor in the high-BMI group (BMI ≥24). TG contributes about 25% to incident NAFLD in people with obesity.

Citing Articles

Development and validation of a nomogram for obesity and related factors to detect gastric precancerous lesions in the Chinese population: a retrospective cohort study.

Shi C, Tao R, Wang W, Tang J, Dou Z, Yuan X Front Oncol. 2024; 14:1419845.

PMID: 39634264 PMC: 11614725. DOI: 10.3389/fonc.2024.1419845.

Metabolic dysfunction-associated steatotic liver disease heterogeneity: Need of subtyping.

Habib S World J Gastrointest Pathophysiol. 2024; 15(2):92791.

PMID: 38845820 PMC: 11151879. DOI: 10.4291/wjgp.v15.i2.92791.

Triglycerides Mediate the Influence of Body Mass Index on Non-Alcoholic Fatty Liver Disease in a Non-Obese Chinese Population with Normal Low-Density Lipoprotein Cholesterol Levels.

Han X, Kong J, Zhang H, Zhao Y, Zheng Y, Wei C Obes Facts. 2024; 17(2):191-200.

PMID: 38266508 PMC: 10987190. DOI: 10.1159/000536447.

Different effects of menopausal hormone therapy on non-alcoholic fatty liver disease based on the route of estrogen administration.

Kim S, Min J, Lee S, Lee D, Choi D Sci Rep. 2023; 13(1):15461.

PMID: 37726372 PMC: 10509271. DOI: 10.1038/s41598-023-42788-6.

The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial.

Bhatt D, Bays H, Miller M, Cain 3rd J, Wasilewska K, Andrawis N Nat Med. 2023; 29(7):1782-1792.

PMID: 37355760 PMC: 10353930. DOI: 10.1038/s41591-023-02427-z.

References

Bray G, Clearfield M, Fintel D, Nelinson D . Overweight and obesity: the pathogenesis of cardiometabolic risk. Clin Cornerstone. 2009; 9(4):30-40. DOI: 10.1016/s1098-3597(09)80003-3. View

Hamaguchi M, Kojima T, Takeda N, Nakagawa T, Taniguchi H, Fujii K . The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med. 2005; 143(10):722-8. DOI: 10.7326/0003-4819-143-10-200511150-00009. View

Huang S, Li J, Shearer G, Lichtenstein A, Zheng X, Wu Y . Longitudinal study of alcohol consumption and HDL concentrations: a community-based study. Am J Clin Nutr. 2017; 105(4):905-912. PMC: 5366050. DOI: 10.3945/ajcn.116.144832. View

Sanyal A, Mirshahi F, Rizzo W, Contos M, Sterling R, Luketic V . Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology. 2001; 120(5):1183-92. DOI: 10.1053/gast.2001.23256. View

. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016; 64(6):1388-402. DOI: 10.1016/j.jhep.2015.11.004. View

Yang W, Xu H, Yu X, Wang Y . Association between retinal artery lesions and nonalcoholic fatty liver disease. Hepatol Int. 2015; 9(2):278-82. PMC: 4387273. DOI: 10.1007/s12072-015-9607-3. View

Wong R, Aguilar M, Cheung R, Perumpail R, Harrison S, Younossi Z . Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology. 2014; 148(3):547-55. DOI: 10.1053/j.gastro.2014.11.039. View

Li J, Huang Z, Hou J, Sawyer A, Wu Z, Cai J . Sleep and CKD in Chinese Adults: A Cross-Sectional Study. Clin J Am Soc Nephrol. 2017; 12(6):885-892. PMC: 5460709. DOI: 10.2215/CJN.09270816. View

Townsend S, Newsome P . Non-alcoholic fatty liver disease in 2016. Br Med Bull. 2016; 119(1):143-56. PMC: 5862239. DOI: 10.1093/bmb/ldw031. View

10.

Choi S, Kim D, Kim H, Kang J, Chung S, Park M . The relation between non-alcoholic fatty liver disease and the risk of coronary heart disease in Koreans. Am J Gastroenterol. 2009; 104(8):1953-60. DOI: 10.1038/ajg.2009.238. View

11.

Dyson J, Jaques B, Chattopadyhay D, Lochan R, Graham J, Das D . Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team. J Hepatol. 2013; 60(1):110-7. DOI: 10.1016/j.jhep.2013.08.011. View

12.

Wu S, Jin C, Li S, Zheng X, Zhang X, Cui L . Aging, Arterial Stiffness, and Blood Pressure Association in Chinese Adults. Hypertension. 2019; 73(4):893-899. DOI: 10.1161/HYPERTENSIONAHA.118.12396. View

13.

Hou X, Zhu Y, Lu H, Chen H, Li Q, Jiang S . Non-alcoholic fatty liver disease's prevalence and impact on alanine aminotransferase associated with metabolic syndrome in the Chinese. J Gastroenterol Hepatol. 2011; 26(4):722-30. DOI: 10.1111/j.1440-1746.2010.06509.x. View

14.

Hamaguchi M, Kojima T, Itoh Y, Harano Y, Fujii K, Nakajima T . The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation. Am J Gastroenterol. 2007; 102(12):2708-15. DOI: 10.1111/j.1572-0241.2007.01526.x. View

15.

Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S . Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology. 2005; 42(1):44-52. DOI: 10.1002/hep.20734. View

16.

Yu J, Shen J, Sun T, Zhang X, Wong N . Obesity, insulin resistance, NASH and hepatocellular carcinoma. Semin Cancer Biol. 2013; 23(6 Pt B):483-91. DOI: 10.1016/j.semcancer.2013.07.003. View

17.

Grander C, Grabherr F, Moschen A, Tilg H . Non-Alcoholic Fatty Liver Disease: Cause or Effect of Metabolic Syndrome. Visc Med. 2016; 32(5):329-334. PMC: 5122994. DOI: 10.1159/000448940. View

18.

Nseir W, Shalata A, Marmor A, Assy N . Mechanisms linking nonalcoholic fatty liver disease with coronary artery disease. Dig Dis Sci. 2011; 56(12):3439-49. DOI: 10.1007/s10620-011-1767-y. View

19.

Masarone M, Federico A, Abenavoli L, Loguercio C, Persico M . Non alcoholic fatty liver: epidemiology and natural history. Rev Recent Clin Trials. 2014; 9(3):126-33. DOI: 10.2174/1574887109666141216111143. View

20.

Badawi A, Klip A, Haddad P, Cole D, Bailo B, El-Sohemy A . Type 2 diabetes mellitus and inflammation: Prospects for biomarkers of risk and nutritional intervention. Diabetes Metab Syndr Obes. 2011; 3:173-86. PMC: 3047967. DOI: 10.2147/dmsott.s9089. View